<p>Atossa Therapeutics, Inc.（納斯達克代碼：ATOS - 獲取免費報告）在 12 月份的空頭頭寸顯著下降。截至 12 月 15 日，空頭頭寸總計為 8,200,000 股，較 11 月 30 日的 11,600,000 股下降了 29.3%。根據 705,500 股的平均日交易量，目前的空頭頭寸比率為 11.6 天。</p>
<p>獲取 <strong>Atossa Therapeutics</strong> 警報：</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師最近對 ATOS 股票發表了評論。HC Wainwright 在 12 月 12 日的報告中重申了對 Atossa Therapeutics 的 “買入” 評級，並給出了 7.00 美元的目標價。Ascendiant Capital Markets 在 12 月 9 日的報告中將 Atossa Therapeutics 的目標價從 6.50 美元上調至 7.00 美元，並給予該公司 “買入” 評級。最後，StockNews.com 在 11 月 18 日的研究報告中將 Atossa Therapeutics 的評級從 “持有” 下調至 “賣出”。</p>
<p><strong>獲取我們關於 ATOS 的最新報告</strong></p>
<h2>Atossa Therapeutics 股票下跌 7.4%</h2>
<p>Atossa Therapeutics 的股票在週五開盤價為 0.98 美元。該公司的市值為 1.2342 億美元，市盈率為-4.46，貝塔係數為 1.21。Atossa Therapeutics 的 52 周低點為 0.77 美元，52 周高點為 2.31 美元。該公司的 50 日簡單移動平均線為 1.27 美元，200 日簡單移動平均線為 1.31 美元。</p>
<h2>Atossa Therapeutics 的機構交易</h2>
<p>一些機構投資者最近調整了他們對 ATOS 的持股。XTX Topco Ltd 在第二季度收購了 Atossa Therapeutics 的新股份，價值約 29,000 美元。Intech Investment Management LLC 在第三季度購買了 Atossa Therapeutics 的新頭寸，價值約 29,000 美元。SG Americas Securities LLC 在第三季度將其在 Atossa Therapeutics 的持股增加了 254.3%。SG Americas Securities LLC 目前擁有 41,849 股該公司的股票，價值 64,000 美元，在此期間又購買了 30,037 股。製造商人壽保險公司在第三季度購買了 Atossa Therapeutics 的新頭寸，價值約 75,000 美元。最後，Rhumbline Advisers 在第二季度收購了 Atossa Therapeutics 的新頭寸，價值約 161,000 美元。目前 12.74% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Atossa Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Atossa Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發針對女性乳腺癌及其他疾病的未滿足醫療需求的藥物。該公司的主要藥物候選者是口服（Z）- 恩多昔芬，作為他莫昔芬的活性代謝物，目前正在進行 II 期臨牀試驗，以治療和預防乳腺癌。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Atossa Therapeutics</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>巴菲特上鈎；伯克希爾在 12 月增持 Oxy</li>
<li>投資汽車股票</li>
<li>2025 年對抗通脹的三大 ETF</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>這三隻芯片股票仍然是 2025 年的買入</li>
</ul>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<p>→ 30 年市場現象開啓過夜機會（來自 ProsperityPub）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng"/></p>
<h2>你現在應該投資 1,000 美元在 Atossa Therapeutics 嗎？</h2>
<p>在你考慮 Atossa Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Atossa Therapeutics 並不在名單上。</p>
<p>雖然 Atossa Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ATOS

<p>Atossa Therapeutics, Inc.（納斯達克代碼：ATOS）在 12 月份的空頭頭寸顯著下降 29.3%，從 11 月份的 11,600,000 股降至 8,200,000 股。目前的空頭頭寸比率為 11.6 天，基於平均每日交易量 705,500 股。分析師們的看法不一，HC Wainwright 和 Ascendiant Capital 維持 “買入” 評級，目標價為 7.00 美元，而 StockNews.com 則將該股票下調至 “賣出”。Atossa 的股票開盤價為 0.98 美元，市值為 1.2342 億美元，市盈率為-4.46</p>

<p>Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a decline of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily trading volume, of 705,500 shares, the short-interest ratio is presently 11.6 days.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc.（納斯達克代碼：ATOS - 獲取免費報告）在 12 月份的空頭頭寸顯著下降。截至 12 月 15 日，空頭頭寸總計為 8,200,000 股，較 11 月 30 日的 11,600,000 股下降了 29.3%。根據 705,500 股的平均日交易量，目前的空頭頭寸比率為 11.6 天。</p>
</div><p>Get <strong>Atossa Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Atossa Therapeutics</strong> 警報：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have recently commented on ATOS shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th. Ascendiant Capital Markets upped their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Monday, December 9th. Finally, StockNews.com downgraded Atossa Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Monday, November 18th.</p>
<div class="lb-trans"><p>一些股票分析師最近對 ATOS 股票發表了評論。HC Wainwright 在 12 月 12 日的報告中重申了對 Atossa Therapeutics 的 “買入” 評級，並給出了 7.00 美元的目標價。Ascendiant Capital Markets 在 12 月 9 日的報告中將 Atossa Therapeutics 的目標價從 6.50 美元上調至 7.00 美元，並給予該公司 “買入” 評級。最後，StockNews.com 在 11 月 18 日的研究報告中將 Atossa Therapeutics 的評級從 “持有” 下調至 “賣出”。</p>
</div><p><strong>Get Our Latest Report on ATOS</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ATOS 的最新報告</strong></p>
</div><h2>Atossa Therapeutics Stock Down 7.4 %</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 股票下跌 7.4%</h2>
</div><p>Shares of Atossa Therapeutics stock opened at $0.98 on Friday. The firm has a market cap of $123.42 million, a price-to-earnings ratio of -4.46 and a beta of 1.21. Atossa Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.31. The company's 50-day simple moving average is $1.27 and its 200-day simple moving average is $1.31.</p>
<div class="lb-trans"><p>Atossa Therapeutics 的股票在週五開盤價為 0.98 美元。該公司的市值為 1.2342 億美元，市盈率為-4.46，貝塔係數為 1.21。Atossa Therapeutics 的 52 周低點為 0.77 美元，52 周高點為 2.31 美元。該公司的 50 日簡單移動平均線為 1.27 美元，200 日簡單移動平均線為 1.31 美元。</p>
</div><h2>Institutional Trading of Atossa Therapeutics</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 的機構交易</h2>
</div><p>A number of institutional investors have recently modified their holdings of ATOS. XTX Topco Ltd acquired a new stake in shares of Atossa Therapeutics during the 2nd quarter worth about $29,000. Intech Investment Management LLC purchased a new position in shares of Atossa Therapeutics in the 3rd quarter worth about $29,000. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock worth $64,000 after buying an additional 30,037 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics in the third quarter valued at about $75,000. Finally, Rhumbline Advisers acquired a new position in shares of Atossa Therapeutics during the second quarter worth about $161,000. 12.74% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了他們對 ATOS 的持股。XTX Topco Ltd 在第二季度收購了 Atossa Therapeutics 的新股份，價值約 29,000 美元。Intech Investment Management LLC 在第三季度購買了 Atossa Therapeutics 的新頭寸，價值約 29,000 美元。SG Americas Securities LLC 在第三季度將其在 Atossa Therapeutics 的持股增加了 254.3%。SG Americas Securities LLC 目前擁有 41,849 股該公司的股票，價值 64,000 美元，在此期間又購買了 30,037 股。製造商人壽保險公司在第三季度購買了 Atossa Therapeutics 的新頭寸，價值約 75,000 美元。最後，Rhumbline Advisers 在第二季度收購了 Atossa Therapeutics 的新頭寸，價值約 161,000 美元。目前 12.74% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Atossa Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Atossa Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.</p>
<div class="lb-trans"><p>Atossa Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發針對女性乳腺癌及其他疾病的未滿足醫療需求的藥物。該公司的主要藥物候選者是口服（Z）- 恩多昔芬，作為他莫昔芬的活性代謝物，目前正在進行 II 期臨牀試驗，以治療和預防乳腺癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Atossa Therapeutics</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Buffett Takes the Bait; Berkshire Buys More Oxy in December</li>
<li>Investing In Automotive Stocks</li>
<li>Top 3 ETFs to Hedge Against Inflation in 2025</li>
<li>What is the Shanghai Stock Exchange Composite Index?</li>
<li>These 3 Chip Stock Kings Are Still Buys for 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Atossa Therapeutics</li>
<li>什麼是低市盈率，它對投資者意味着什麼？</li>
<li>巴菲特上鈎；伯克希爾在 12 月增持 Oxy</li>
<li>投資汽車股票</li>
<li>2025 年對抗通脹的三大 ETF</li>
<li>上海證券交易所綜合指數是什麼？</li>
<li>這三隻芯片股票仍然是 2025 年的買入</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><p>→ 30-year market phenomenon opens up overnight opportunity (From ProsperityPub)(Ad)</p>
<div class="lb-trans"><p>→ 30 年市場現象開啓過夜機會（來自 ProsperityPub）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDg5Ng" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10896&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Atossa Therapeutics right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Atossa Therapeutics 嗎？</h2>
</div><p>Before you consider Atossa Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Atossa Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Atossa Therapeutics 並不在名單上。</p>
</div><p>While Atossa Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Atossa Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Atossa Therapeutics, Inc.（納斯達克股票代碼：ATOS）的空頭頭寸大幅減少